section name header

Pronunciation

mo-DAF-i-nil

Classifications

Therapeutic Classification: central nervous system stimulants

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Rapidly absorbed; bioavailability unknown.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Highly (90%) metabolized by the liver; <10% eliminated unchanged in the urine.

Half-life: 15 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid2–4 hr24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: arrhythmias, chest pain, hypertension, hypotension, syncope.

Derm: dry skin, rash, STEVENS-JOHNSON SYNDROME (SJS).

EENT: rhinitis, abnormal vision, amblyopia, epistaxis, pharyngitis.

Endo: hyperglycemia.

F and E: thirst.

GI: liver enzymes, nausea, anorexia, diarrhea, gingivitis, mouth ulcers, vomiting.

GU: abnormal ejaculation, albuminuria, urinary retention.

Hemat: eosinophilia.

MS: joint disorder, neck pain.

Neuro: headache, aggression, amnesia, anxiety, ataxia, cataplexy, confusion, delusions, depression, dizziness, dyskinesia, hallucinations, hypertonia, insomnia, mania, paresthesia, SEIZURES, SUICIDAL IDEATION, tremor.

Resp: dyspnea.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS , infection.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Hepatic Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Provigil

Canadian Brand Names

Alertec

Contr. Subst. Schedule

Schedule IV (C-IV)